A new intraocular mini-telescope is easy to implant through a small incision and has optimized optics so that it reliably provides good quality vision.
London—A new intraocular mini-telescope (iolAMD, London Eye Hospital Pharma) offers significant surgical and optical advantages compared with previous technology, and its features make it an exciting advance for cataract surgery patients with vision loss related to macular disease.
“The new IOL allows for happy patients, because it is associated with faster visual rehabilitation compared with previous intraocular telescopes and better quality vision,” said Bobby Qureshi, MD, consultant ophthalmic surgeon, and chief medical officer and founder, London Eye Hospital Pharma, London.
“In addition, it makes for happier surgeons,” Dr. Qureshi added. “The implantation procedure is simple and fast, has a short learning curve because it involves existing skills, and it has safety advantages because the lenses are injected through a small incision and situated in the posterior chamber, away from sensitive corneal structures.”
Age-related macular degeneration (AMD) is the most common cause of blindness in people over age 55 in the developed world, with more than 20 million sufferers in the United States and between 200 million to 300 million worldwide. It is estimated that by 2020, there will be nearly 30 million cases of AMD in the United States alone, noted Rob Hill, chief executive officer, London Eye Hospital Pharma, London.
“[The innovation] is the first patient- and surgeon-friendly procedure to address the symptoms of dry AMD,” Hill said.